Fosun Pharma: The registration application for the holding company's cyclophosphamide injection has been accepted.

Fosun Pharma announced that its holding subsidiary, Gisti Pharma Limited, has had its registration application for cyclophosphamide injection accepted by the National Medical Products Administration. This drug, independently developed by the group, is intended for the treatment of various diseases. As of December 2025, the group has invested approximately 7.4 million yuan in research and development for this drug. In 2024, sales of cyclophosphamide injection in the domestic market were approximately 291 million yuan. Commercial production of this drug requires regulatory approval, and the acceptance of this application does not have a significant impact on current performance. There is uncertainty in the sales situation of the drug.